These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38708616)

  • 1. Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States.
    Wu C; Song Z; Balachandra S; Dream S; Chen H; Rose JB; Bhatia S; Gillis A
    Ann Surg; 2024 May; ():. PubMed ID: 38708616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second primary cancers and survival among neuroendocrine tumor patients.
    Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer of the Larynx-20-Year Comparative Survival and Mortality Analysis by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration and ICD-O-3 Topographic Primary Sites-Codes C32.0-9: A Systematic Review of 43,103 Cases for Diagnosis Years 1975-2017: (NCI SEER*Stat 8.3.9).
    Milano AF
    J Insur Med; 2024 Jul; 51(2):92-110. PubMed ID: 39266004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
    Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
    Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
    Gosain R; Ball S; Rana N; Groman A; Gage-Bouchard E; Dasari A; Mukherjee S
    Cancer; 2020 Feb; 126(4):792-799. PubMed ID: 31714595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
    Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
    Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors.
    Shen C; Gu D; Zhou S; Xu Y; Sarshekeh AM; Halperin D; Shih YT; Yao JC; Dasari A
    Pancreas; 2019; 48(10):1373-1379. PubMed ID: 31688604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global burden of neuroendocrine tumors and changing incidence in Kentucky.
    Chauhan A; Yu Q; Ray N; Farooqui Z; Huang B; Durbin EB; Tucker T; Evers M; Arnold S; Anthony LB
    Oncotarget; 2018 Apr; 9(27):19245-19254. PubMed ID: 29721198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
    Yao JC; Hassan M; Phan A; Dagohoy C; Leary C; Mares JE; Abdalla EK; Fleming JB; Vauthey JN; Rashid A; Evans DB
    J Clin Oncol; 2008 Jun; 26(18):3063-72. PubMed ID: 18565894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumor epidemiology: contrasting Norway and North America.
    Hauso O; Gustafsson BI; Kidd M; Waldum HL; Drozdov I; Chan AK; Modlin IM
    Cancer; 2008 Nov; 113(10):2655-64. PubMed ID: 18853416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.
    Sackstein PE; O'Neil DS; Neugut AI; Chabot J; Fojo T
    Semin Oncol; 2018 Aug; 45(4):249-258. PubMed ID: 30348533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador.
    Escobar KM; Vicente-Villardon JL; Villacís Gonzalez RE; Castillo Cordova PH; Sánchez Rodríguez JM; De la Cruz-Velez M; Siteneski A
    Healthcare (Basel); 2022 Aug; 10(8):. PubMed ID: 36011226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
    Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
    Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.
    Alvarez CS; Piazuelo MB; Fleitas-Kanonnikoff T; Ruhl J; Pérez-Fidalgo JA; Camargo MC
    JAMA Netw Open; 2024 Aug; 7(8):e2428828. PubMed ID: 39158910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation.
    Zhao F; Huang L; Wang Z; Wei F; Xiao T; Liu Q
    Front Endocrinol (Lausanne); 2023; 14():1061187. PubMed ID: 36817582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.